Sanofi receives positive CHMP opinion for Sarclisa® (isatuximab) for the treatment of relapsed and refractory multiple myeloma

Sanofi and Translate Bio collaborate to develop novel mRNA vaccine candidate against COVID-19

Sanofi successfully prices EUR 1.5 billion of bond issue

Sanofi : Filing of the 2019 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report

Sanofi's Board of Directors proposes the appointment of Rachel Duan and Lise Kingo as independent directors

Sanofi : FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma

Sanofi to create new industry leading European company to provide active pharmaceutical ingredients (API*)

Sanofi joins forces with U.S. Department of Health and Human Services to advance a novel coronavirus vaccine

Sanofi delivers strong 2019 business EPS growth of 6.8% at CER

Sanofi : Sanofi brain-penetrant BTK inhibitor meets primary endpoint of Phase 2 trial in relapsing multiple sclerosis